Announcing Research 101 | UMR Answers Common Questions About NIH Research in this New Fact Sheet Series
Why Invest in NIH Research? | UMR Offers Fact Sheets Explaining Why Congress Must #keepNIHstrong
Read UMR's Statement on the House Appropriations Committee's Passage of FY23 Labor-HHS Funding Bill
NIH's Role In Sustaining the U.S. Economy | 2022 Update Now Available

A participant in the NIH 2019-2020 Medical Research Scholars Program.

Photo Credit: National Institutes of Health

About This Photo

Despite Spreading Easily, Delta Is Uniquely Weak Against Covid-19 Antibodies, Study Finds

Despite the emergence of delta as the dominant variant of Covid-19 in the U.S., nearly all of the antibodies produced by the Pfizer vaccine are able to neutralize it, according to a study published Monday, underscoring the protection offered by vaccinations in a pandemic where nearly all cases—and virtually all serious cases—are among the unvaccinated.

“In face of vaccination, delta is relatively a wimpy virus,” said Ali Ellebedy, a senior co-author of the study and a professor of pathology and immunology at Washington University School of Medicine in St. Louis, in a press release announcing the study. “If we had a variant that was more resistant like beta but spread as easily as delta, we’d be in more trouble.”